Latest Drugs & Vaccines stories in Health, with AI-generated summaries from NewsSnap.ai.
Start a 30-day free trial to follow this topic and get personalized updates.
Follow Drugs & VaccinesThe U.S. FDA has granted Fast-Track Designation to BioVersys AG for its investigational antimicrobial agent, BV100. This designation accelerates the development and review of BV100, recognizing the urgent need for new treatments against serious infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, particularly hospital-acquired or ventilator-associated bacterial pneumonia.
The U.S. FDA has approved Gilead Sciences' Bixlenvo, a new once-daily single-tablet regimen for adults with HIV-1 who are virologically suppressed. This combination of bictegravir 75 mg and lenacapavir 50 mg offers a simpler treatment option, particularly benefiting patients who previously managed complex multi-tablet therapies due to resistance or tolerability issues, thereby improving adherence and quality of life.